search
Back to results

Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam

Primary Purpose

Length of Pregnancy Prolongation in Hours

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
erythromycin and metronidazole (antibiotics)
placebo
Sponsored by
MetroHealth Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Length of Pregnancy Prolongation in Hours focused on measuring Preterm birth, antibiotics, preterm labor, respiratory distress, pergnancy

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. All patients admitted with the diagnosis of preterm labor between 24 0/7 and 33 6/7 weeks gestation. Preterm labor will be defined by regular contractions and/or cervical change from last documented exam.
  2. Cervical exam 4 cm or greater
  3. Intact membranes

Exclusion Criteria:

  1. Multiple gestation (>2)
  2. Clinical evidence of chorioamnionitis, such as maternal fever, uterine tenderness, fetal tachycardia
  3. Lethal fetal anomaly
  4. Persistent vaginal bleeding, abruption, or placenta previa
  5. Rupture of membranes
  6. Maternal illness or fetal indication requiring delivery
  7. Inability to give informed consent
  8. Serious allergy to study medications. GI discomfort will not be considered a drug allergy

Sites / Locations

  • MetroHealth Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

A

B

Arm Description

roup A will be assigned to receive antibiotics: Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days. Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days.

Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.

Outcomes

Primary Outcome Measures

Length of Pregnancy Prolongation
The length of time (in hours) from initiation of therapy to delivery will establish the latency

Secondary Outcome Measures

Respiratory Distress
Respiratory distress will be defined by the clinical record documentation of the neonatal team.

Full Information

First Posted
December 27, 2007
Last Updated
August 13, 2019
Sponsor
MetroHealth Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00589329
Brief Title
Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam
Official Title
Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Terminated
Why Stopped
published data suggest potential harm in other investigations.
Study Start Date
December 2007 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
October 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
MetroHealth Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Preterm birth remains a major health concern affecting up to 12% of all live births prior to 37 weeks gestation. As preterm birth can often be associated with infection our proposal is to evaluate in a randomized fashion antibiotics for women with advanced cervical exams.
Detailed Description
Preterm birth, its causes, prevention, complications and ramifications persist as an important focus of obstetrical research. In the United States 11.8% of all live births occur prior to 37 weeks gestation. As many as 45% of these deliveries will have been proceeded by preterm labor with intact membranes.(2) Both preterm labor and preterm premature rupture of membranes have both been associated with evidence intrauterine infection. While antibiotic treatment in conservative management of preterm PROM remote from term has been shown to significantly prolong pregnancy and reduce infant morbidity, (16) data regarding the effectiveness of antibiotics for pregnancy prolongation in preterm labor are inconsistent. (3-15) Currently, narrow spectrum antibiotics (penicillin or clindamycin) are given prior to delivery to reduce the risk of neonatal Group B Beta Streptococcus (GBS) sepsis, however broad spectrum antibiotic treatment of women with preterm labor for pregnancy prolongation is not recommended. Review of the literature regarding antibiotic treatment for pregnancy prolongation in preterm labor reveals that most studies utilized single agent therapy, and no study has evaluated the use of antibiotics for pregnancy prolongation in women with an advanced cervical exam (>4cm). While a number of studies have shown significant pregnancy prolongation in unselected populations,(5,12,13) only one study of 12 reviewed was able to show a neonatal benefit to adjunctive antibiotic use.(12,20) Norman, et al was able to show a reduction in the incidence of necrotising enterocolitis with the use of antibiotics. Given the number of studies in this area, and the lack of supporting evidence, this likely represents an alpha error. Another study by Svare et al was able to show a significant decrease in NICU admissions for women treated with antibiotics in the setting of preterm labor, however no change was reported in neonatal morbidities. Our proposed study is designed to evaluate patients at particular risk for preterm delivery; those with advanced cervical exam. In this randomized prospective controlled study, we intend to examine the influence of adjunctive antibiotic use in preterm labor complicated by a cervical exam of 4 cm or greater. We plan to compare a study group receiving broad-spectrum antibiotics with a control group that will not receive antibiotics for pregnancy prolongation. Both groups will receive antibiotics for GBS prophylaxis as indicated. We hope to see a delay in delivery in the study group as a primary outcome. Secondary outcomes will include the use of steroids, neonatal complications including sepsis, intraventricular hemorrhage, periventricular leukomalacea, mechanical ventilation and respiratory distress syndrome, retinopathy of prematurity and necrotizing enterocolitis, and neonatal ICU stay.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Length of Pregnancy Prolongation in Hours
Keywords
Preterm birth, antibiotics, preterm labor, respiratory distress, pergnancy

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
roup A will be assigned to receive antibiotics: Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days. Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days.
Arm Title
B
Arm Type
Placebo Comparator
Arm Description
Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
Intervention Type
Drug
Intervention Name(s)
erythromycin and metronidazole (antibiotics)
Intervention Description
Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days. Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
IV and pill placebo
Primary Outcome Measure Information:
Title
Length of Pregnancy Prolongation
Description
The length of time (in hours) from initiation of therapy to delivery will establish the latency
Time Frame
Measured from randomization to delivery in hours
Secondary Outcome Measure Information:
Title
Respiratory Distress
Description
Respiratory distress will be defined by the clinical record documentation of the neonatal team.
Time Frame
newborn nursery

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All patients admitted with the diagnosis of preterm labor between 24 0/7 and 33 6/7 weeks gestation. Preterm labor will be defined by regular contractions and/or cervical change from last documented exam. Cervical exam 4 cm or greater Intact membranes Exclusion Criteria: Multiple gestation (>2) Clinical evidence of chorioamnionitis, such as maternal fever, uterine tenderness, fetal tachycardia Lethal fetal anomaly Persistent vaginal bleeding, abruption, or placenta previa Rupture of membranes Maternal illness or fetal indication requiring delivery Inability to give informed consent Serious allergy to study medications. GI discomfort will not be considered a drug allergy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brian Mercer, M.D.
Organizational Affiliation
MetroHealth Medical Center MFM Director
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Thaddeus Waters, M.D.
Organizational Affiliation
MetroHealth Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
MetroHealth Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44109
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam

We'll reach out to this number within 24 hrs